Suven Life Sciences Limited (BOM:530239)
136.90
+1.65 (1.22%)
At close: Jan 22, 2026
Suven Life Sciences Employees
Suven Life Sciences had 138 employees as of March 31, 2025. The number of employees decreased by 3 or -2.13% compared to the previous year.
Employees
138
Change (1Y)
-3
Growth (1Y)
-2.13%
Revenue / Employee
424.84K INR
Profits / Employee
-15.35M INR
Market Cap
30.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 138 | -3 | -2.13% |
| Mar 31, 2024 | 141 | 10 | 7.63% |
| Mar 31, 2023 | 131 | 14 | 11.97% |
| Mar 31, 2022 | 117 | -13 | -10.00% |
| Mar 31, 2021 | 130 | -12 | -8.45% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IOL Chemicals and Pharmaceuticals | 2,891 |
| Neuland Laboratories | 1,794 |
| Shilpa Medicare | 998 |
| Bajaj HealthCare | 918 |
| NGL Fine-Chem | 520 |
| Sudeep Pharma | 480 |
| Gujarat Themis Biosyn | 221 |
| Influx Healthtech | 163 |
Suven Life Sciences News
- 6 weeks ago - Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder - Business Upturn
- 1 year ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 1 year ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn
- 1 year ago - Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder - Business Upturn
- 1 year ago - Suven Life Sciences announces FDA acceptance of Investigational New Drug - Business Upturn